RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, Ohio. Electronic address: .
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 11/2012; 85(5). DOI: 10.1016/j.ijrobp.2012.10.008
Source: PubMed

ABSTRACT PURPOSE: To determine the safety and efficacy of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed glioblastoma (GBM) patients. METHODS AND MATERIALS: Between March 21, 2002, and May 3, 2004, Radiation Therapy Oncology Group (RTOG) 0211 enrolled 31 and 147 GBM patients in the phase 1 and 2 arms, respectively. Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy (RT) and continued post RT for 18 months or until progression. Tissue microarrays from 68 cases were analyzed for EGFR expression. RESULTS: The maximum tolerated dose (MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs (non-EIAEDs). All patients in the phase 2 component were treated at a gefitinib dose of 500 mg; patients receiving EIADSs could be escalated to 750 mg. The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal. Median survival was 11.5 months for patients treated per protocol. There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone, matched by RTOG recursive partitioning analysis (RPA) class distribution. Younger age was significantly associated with better outcome. Per protocol stratification, EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients. CONCLUSIONS: The addition of gefitinib to RT is well tolerated. Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone.

Download full-text


Available from: Minesh P Mehta, Feb 18, 2015
1 Follower
  • Source
    • "2010 II NSCLC 66 Gy þ gefitinib after induction chemotherapy Survival of poor-risk patients was promising, but for good-risk patients was disappointing. Gefitinib [29] 2011 II HNSCC 70 Gy þ cisplatin þ gefitinib Well tolerated but did not improve efficacy Gefitinib [30] 2012 II NSCLC þ brain metastasis 30 Gy þ gefitinib or temozolomide Well tolerated but study did not support use of combination as PFS and OS poor Gefitinib [31] 2013 I/II Glioblastoma 60 Gy þ gefitinib Well tolerated, no improvement in outcome Lapatinib [32] 2012 I Breast 35e70 Gy þ lapatinib Well tolerated, response rates comparable to other studies NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; 5-FU, 5-fluorouracil; IR, irradiation (dose variable); CRR, complete remission rate; PFS, progression-free survival; CR, complete remission, QoL, quality of life; OS, overall survival. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy. There are good preclinical data to suggest this approach worthy of investigation and in this review we discuss how this has translated into recent clinical trials. The outcome of clinical trials investigating radiotherapy/targeted drug combinations published in the last 5 years is discussed, as are trials in progress. The perceived future opportunities and challenges in the development of this exciting area are considered.
    Clinical Oncology 03/2014; 26(5). DOI:10.1016/j.clon.2014.02.006 · 2.83 Impact Factor
  • International journal of radiation oncology, biology, physics 07/2013; 86(3):398-399. DOI:10.1016/j.ijrobp.2013.02.029 · 4.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important molecular pathways associated with aberrant activation or suppression of cellular signal transduction pathways involved in gliomagenesis, including epidermal growth factor receptor, vascular endothelial growth factor receptor, mammalian target of rapamycin, and integrins signaling pathways. The use of antiangiogenic agent bevacizumab, epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib, mammalian target of rapamycin inhibitors temsirolimus and everolimus, and integrin inhibitor cilengitide, in combination with radiation therapy, has been supported by encouraging preclinical data, resulting in a rapid translation into clinical trials. Currently, the majority of published clinical studies on the use of these agents in combination with radiation and cytotoxic therapies have shown only modest survival benefits at best. Tumor heterogeneity and genetic instability may, at least in part, explain the poor results observed with a single-target approach. Much remains to be learned regarding the optimal combination of targeted agents with conventional chemoradiation, including the use of multipathways-targeted therapies, the selection of patients who may benefit from combined treatments based on molecular biomarkers, and the verification of effective blockade of signaling pathways.
    OncoTargets and Therapy 08/2013; 6:1079-95. DOI:10.2147/OTT.S48224 · 2.31 Impact Factor
Show more